We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New ELISA Kit Measures Chronic Kidney Disease Biomarker

By LabMedica International staff writers
Posted on 05 May 2015
Print article
Image: The FGF23 ELISA kit extends the existing line of Biomedica assays directed against chronic kidney disease (Photo courtesy of Biomedica Immunoassays).
Image: The FGF23 ELISA kit extends the existing line of Biomedica assays directed against chronic kidney disease (Photo courtesy of Biomedica Immunoassays).
A new ELISA kit has been released that is expected to become a valuable tool for researchers investigating new biomarkers that could improve prediction of chronic kidney disease (CKD) progression, as well as discovery of new drug targets.

The emergence of FGF23 as a potentially modifiable risk factor in CKD has led to growing interest in its measurement as a tool to assess patient risk and target therapy. In this regard, Biomedica Immunoassays (Vienna, Austria) has launched the first European CE marked FGF23 (C-terminal) ELISA assay that specifically detects both intact and C-terminal fragments of FGF23 in human serum and plasma. FGF23 (fibroblast growth factor 23) is a 32 kDa protein with 251 amino acids that is proteolytically processed between arginine179 and serine180 to generate N-terminal and C-terminal fragments. FGF23 is mainly secreted by osteocytes and controls phosphate and 1,25(OH)2 vitamin D homeostasis.

The kit comprises a sandwich enzyme immunoassay for the direct determination of FGF23 in human serum and plasma samples. In a first step, standards, samples, controls, and detection antibody (rabbit polyclonal anti-human FGF23-biotin) are dispensed into the wells of microtiter strips, which have been pre-coated with anti-FGF23 antibody. FGF23 present in the standards, samples, or controls binds to the pre-coated antibody in the well and forms a sandwich with the detection antibody. In the washing step all nonspecific unbound material is removed. In a second step, the conjugate (Streptavidin-horse radish peroxidase) is added to the wells and reacts with the detection antibody through avidin-biotin binding. After another washing step, the TMB (tetramethylbenzidine) substrate is dispensed into the wells. The enzyme catalyzed color change of the substrate is directly proportional to the amount of FGF23. This color change is detectable with a standard microtiter plate ELISA reader. A dose response curve of the absorbance (optical density at 450 nanometers) versus standard concentration is generated, using the values obtained from the standard. The concentration of FGF23 in the sample is determined directly from the dose response curve.

FGF23 is associated with cardiovascular and renal outcomes in patients with CKD and adds value to risk assessments based on conventional risk factors. “In particular, the ability to measure FGF23 in both serum and plasma samples and its stability in both matrices after sample collection opens up a significant new capability to learn about the mechanisms driving FGF 23 elevations in CKD,” said Dr. Wolfgang Woloszczuk, CSO of Biomedica Gruppe.


Related Links:
Biomedica Immunoassays

New
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Unit-Dose Packaging solution
HLX
New
CVD Risk Test
GammaCoeur CVD Risk ELISA Test
New
Silver Member
Static Concentrator
BJP 10

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.